Onkologie. 2025:19(3):137-143 | DOI: 10.36290/xon.2025.027

Febrile neutropenia

Ondřej Lukáč1, Lukáš Kohout2
1 Klinika Hemato-onkologie a buněčné terapie, Univerzitní nemocnice Magdeburg
2 Klinika infekčních nemocí a cestovní medicíny 2. LF UK a FN Motol, Praha

Febrile neutropenia represents one of the most serious and common acute situations in oncology. It is defined as a condition in which a cancer patient's temperature rises above 38 °C for more than 1 hour or rises above 38 °C twice in 12 hours, and the neutrophil count is ≤ 0.5 × 109/l or below 1.0 × 109/l with a further decline expected. These infections tend to be very aggressive and unrestricted, and less frequent viral (e. g. CMV infections) or mycotic infections occur. They therefore represent a significant clinical challenge.

Keywords: infections, neutropenia, febrile, antibiotics, bacteria, viruses, fungi.

Accepted: June 26, 2025; Published: July 4, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lukáč O, Kohout L. Febrile neutropenia. Onkologie. 2025;19(3):137-143. doi: 10.36290/xon.2025.027.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF

    References

    1. . De Castro Carpeño J, Gascón-Vilaplana P, et al. Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study. Mol Clin Oncol. 2015;3(3):725-729. doi: 10.3892/mco.2015.524. Epub 2015 Mar 5. PMID: 26137294; PMCID: PMC4471542. Go to original source... Go to PubMed...
    2. . Hosiriluck N, Klomjit S, Rassameehiran S, et al. Prognostic factors for mortality with febrile neutropenia in hospitalized patients. The Southwest Respiratory and Critical Care Chronicles. 2015;3(9):3-13. Available from: https://pulmonarychronicles.com/index.php/pulmonarychronicles/article/view/188. Go to original source...
    3. . Herold V. Onkologie. In Internistische Intensivmedizin. 2020;1213-1216. Printgallery.
    4. . Moreau M, Klastersky J, Schwarzbold A, et al. A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol. 2009;20(3): 513-519. doi: 10.1093/annonc/mdn655. Epub 2009 Jan 12. PMID: 19139177. Go to original source... Go to PubMed...
    5. . Ba Y, Shi Y, Jiang W, et al. Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association. Cancer Biol Med. 2020;17(4):896-909. doi: 10.20892/j.issn.2095-3941.2020.0069. Epub 2020 Dec 15. PMID: 33299642; PMCID: PMC7721096. Go to original source... Go to PubMed...
    6. . Hartmann LC, Tschetter LK, Habermann TM, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med. 1997;336(25):1776-1780. doi: 10.1056/NEJM199706193362502. PMID: 9187067. Go to original source... Go to PubMed...
    7. . Guideline for the use of granulocyte-colony stimulating factor (G-CSF) in adult oncology and haematology patients (Northern Cancer Alliance). Available from: https://www.northerncanceralliance.nhs.uk/wp-content/uploads/2018/11/GCSF-Guidelines-Northern-Cancer-Alliance-January-2018-v1.5.pdf.
    8. . Mank A, van der Lelie H. Is there still an indication for nursing patients with prolonged neutropenia in protective isolation? An evidence-based nursing and medical study of 4 years experience for nursing patients with neutropenia without isolation. Eur J Oncol Nurs. 2003;7(1):17-23. doi: 10.1054/ejon.2002.0216. PMID: 12849571. Go to original source... Go to PubMed...
    9. . Srividyalakshmi S, Baumann M. Reverse isolation for neutropenic patients. Community Oncology. 2008;5:628-632. 10.1016/S1548-5315(11)70529-0. Go to original source...
    10. . Sonbol MB, Jain T, Firwana B, et al. Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis. BMJ Support Palliat Care. 2019;9(4):425-433. doi: 10.1136/bmjspcare-2018-001742. Epub 2019 Apr 4. PMID: 30948447. Go to original source... Go to PubMed...
    11. . Özdemir SK, Iltar U, Salim O, et al. Investigation of seasonal frequency and pathogens in febrile neutropenia. Memo. 2019;12(2):119-122. doi: 10.1007/s12254-018-0468-z. Epub 2019 Jan 15. PMID: 32218873; PMCID: PMC7091104. Go to original source... Go to PubMed...
    12. . Cullen M, Baijal S. Prevention of febrile neutropenia: use of prophylactic antibiotics. Br J Cancer. 2009;101 Suppl 1(Suppl 1):S11-4. doi: 10.1038/sj.bjc.6605270. PMID: 19756000; PMCID: PMC2752225. Go to original source... Go to PubMed...
    13. . Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010;27(3):193-209. doi: 10.2165/11531490-000000000-00000. PMID: 20210367. Go to original source... Go to PubMed...
    14. . Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics.
    15. . DeVoe C, Trinh TD, Moises J, et al. Oral Third-Generation Cephalosporins vs. Levofloxacin for Antibacterial Prophylaxis in Neutropenic Patients with Hematologic Malignancies. Open Forum Infect Dis. 2019;6(Suppl 2):S943. doi: 10.1093/ofid/ofz360.2362. PMCID: PMC6810486. Go to original source...
    16. . Chong Y, Shimoda S, Miyake N, et al. Incomplete recovery of the fecal flora of hematological patients with neutropenia and repeated fluoroquinolone prophylaxis. Infect Drug Resist. 2017;10:193-199. doi: 10.2147/IDR.S133333. PMID: 28721078; PMCID: PMC5500534. Go to original source... Go to PubMed...
    17. . Goering V, Dockrell H, Zuckerman M et al, Mimsova lekarska mikrobiologie. Praha: Triton; 2016.
    18. . Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol. 1998;16:1179-1187. Go to original source... Go to PubMed...
    19. . Rolston KVI, Raad J, Whimbey E, et al. The changing spectrum of bacterial infections in febrile neutropenic patients. In Klastersky JA, editor. Febrile neutropenia. Berlin: Springer- Verlag 1997;53-56. Go to original source...
    20. . Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in epidemiology of noso- comial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36:1003-1110. Go to original source... Go to PubMed...
    21. . Freifeld AG, Bow EJ, Sepkowitz KA. Clinical practice guideline for the use of antimicrobial agents in neutropenic pacients with cancer: 2010 update by the infectious diseases society of America. Clin Inf Diseases. 2011;52(4):e56-93.
    22. . Kontoyiannis DP, Reddy BT, Hanna H, et al. Breakthrough candide- mia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity. Infect Control Hosp Epidemiol. 2002;23:542-545. Go to original source... Go to PubMed...
    23. . Ohrmalm L, Wong M, Aust C, et al. Viral findings in adult hematological patients with neutropenia. PLoS One. 2012;7(5):e36543. doi: 10.1371/journal.pone.0036543. Epub 2012 May 3. Go to original source... Go to PubMed...
    24. . Klastersky J. Therapy of Infections in Cancer Patients, In Handbook of Supportive Care in Cancer, Marcel Dekker. New York: Inc.;1995:1-44.
    25. . Kern WV, Marchetti O, Drgona L, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy - EORTC infectious diseases group trial XV. J Clin Oncol. 2013;31(9):1149-1156. doi: 10.1200/JCO.2012.45.8109. Epub 2013 Jan 28. PMID: 23358983. Go to original source... Go to PubMed...
    26. . Raad I, Hanna HA, Alakech B, et al. Differential time to positivity: a useful method for diagnosing catheter-related blood­stream infections. Ann Intern Med. 2004;140(1):18-25. doi: 10.7326/0003-4819-140-1-200401060-00007. PMID: 14706968. Go to original source... Go to PubMed...
    27. . Obrová K, Grumaz S, Remely M, et al. Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasms. Am J Hematol. 2021;96(6):719-726. doi: 10.1002/ajh.26177. Epub 2021 May 3. PMID: 33784434. Go to original source... Go to PubMed...
    28. . Mariana C, Olivier P, Christian TL, et al. Current microbiological testing approaches and documented infections at febrile neutropenia onset in patients with hematologic malignancies. Int J Infect Dis. 2024;147:107183. doi: 10.1016/j.ijid.2024.107183. Epub 2024 Jul 29. PMID: 39084344. Go to original source... Go to PubMed...
    29. . Heussel CP. Diagnostic Radiology in Hematological Patients with Febrile Neutropenia. Infections in Hematology. 2014:113-35. doi: 10.1007/978-3-662-44000-1_7. PMCID: PMC7122774. Go to original source...
    30. . Larke FJ, Kruger RL, Cagnon CH, et al. Estimated radiation dose associated with low-dose chest CT of average-size participants in the National Lung Screening Trial. AJR Am J Roentgenol. 2011;197(5):1165-1169. doi: 10.2214/AJR.11.6533. PMID: 22021510. Go to original source... Go to PubMed...
    31. . Machetti M, Furfaro E, Viscoli C. Galactomannan in piperacillin-tazobactam: how much and to what extent? Anti­microb Agents Chemother. 2005;49(9):3984-3985. doi: 10.1128/AAC.49.9.3984-3985.2005. PMID: 16127090; PMCID: PMC1195433. Go to original source... Go to PubMed...
    32. . Nucci M. How I Treat Febrile Neutropenia. Mediterr J Hematol Infect Dis. 2021;13(1):e2021025. doi: 10.4084/MJHID.2021.025. PMID: 33747406; PMCID: PMC7938921. Go to original source... Go to PubMed...
    33. . European Organization for Research nad Treatment of cancer (EORTC) International Anti- microbial Therapy Cooperative Group. Vancomycin added to empirical combiantion antibiotic therapy for fever in granulocytopenic cancer patiens. J Infect Dis 1991;163:951-958. Go to original source...
    34. . Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56-93. doi: 10.1093/cid/cir073. PMID: 21258094. Go to original source... Go to PubMed...
    35. . Klastersky, Naurosis JD, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines, Ann Oncol. 2016;27(suppl 5):v111-v118. Go to original source... Go to PubMed...
    36. . Mariana C, Olivier P, Christian TL, et al. Current microbiological testing approaches and documented infections at febrile neutropenia onset in patients with hematologic malignancies. Int J Infect Dis. 2024;147:107183. Go to original source... Go to PubMed...
    37. . Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J; ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111-v118. doi: 10.1093/annonc/mdw325. PMID: 27664247. Go to original source... Go to PubMed...
    38. . Tsuchihashi K, Ito M, Okumura Y, et al. Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology. Int J Clin Oncol. 2024;29:700-705. https://doi.org/10.1007/s10147-024-02541-z. Go to original source... Go to PubMed...
    39. . Kobayashi R, Hori D, Sano H,et al. Meropenem versus piperacillin/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia in pediatric patients. J Microbiol Immunol Infect. 2018;51(4):473-477. doi: 10.1016/j.jmii.2017.06.005. Epub 2017 Jun 29. PMID: 28690028. Go to original source... Go to PubMed...
    40. . Mariana C, Olivier P, Christian TL, et al. Current microbiological testing approaches and documented infections at febrile neutropenia onset in patients with hematologic malignancies. Int J Infect Dis. 2024;147:107183. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.